Related Experiment Videos
Thalidomide in cancer medicine
V Eleutherakis-Papaiakovou1, A Bamias, M A Dimopoulos
1Department of Clinical Therapeutics, University of Athens, School of Medicine, Athens, Greece.
Summary
Thalidomide shows significant activity in multiple myeloma and may help reduce transfusions in myelofibrosis. Its effectiveness in solid tumors is limited, but promising when combined with other treatments for specific cancers.
Area of Science:
- Oncology
- Pharmacology
Background:
- Thalidomide is an oral medication with antiangiogenic and immunomodulatory effects.
- It is under extensive investigation for advanced cancer management.
Purpose of the Study:
- To review the efficacy of thalidomide in various advanced cancers.
- To assess its role in hematologic malignancies and solid tumors.
Main Methods:
- Review of multiple clinical studies and patient data.
- Analysis of thalidomide's activity as a monotherapy and in combination treatments.
Main Results:
- Significant activity observed in multiple myeloma.
- Potential to reduce transfusion needs in myelofibrosis and myelodysplastic syndromes.
- Limited but promising activity in Kaposi's sarcoma, malignant melanoma, renal cell, and prostate cancers, especially in combination therapy.
- Minimal to no activity in glioma, head and neck, breast, and ovarian cancers.
Conclusions:
- Thalidomide is a valuable therapeutic option for multiple myeloma.
- Its role in solid tumors is less defined but shows potential in specific combinations.
- Further research is warranted for optimizing thalidomide use in different cancer types.